Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 9/20 | 0.49 |
| ▸ | EGFR | P00533 | 8/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305275 | 1.00 | FLT1 (0.49) | FLT1EGFRADORA2AADORA3ADORA2B | |
| SCHEMBL6301850 | 1.00 | FLT1 (0.49) | FLT1EGFRADORA2AADORA3ADORA2B | |
| SCHEMBL6302384 | 0.91 | FLT1 (0.51) | FLT1EGFRADORA2AADORA2BKDR | |
| SCHEMBL6309330 | 0.91 | FLT1 (0.51) | FLT1EGFRADORA2AADORA2BKDR | |
| SCHEMBL6302403 | 0.91 | FLT1 (0.51) | FLT1EGFRADORA2AADORA2BKDR | |
| SCHEMBL6305222 | 0.91 | SYK (0.48) | FLT1EGFRKDRMETSYK | |
| SCHEMBL6304469 | 0.91 | SYK (0.48) | FLT1EGFRKDRMETSYK | |
| SCHEMBL6304461 | 0.91 | SYK (0.48) | FLT1EGFRKDRMETSYK | |
| SCHEMBL6625751 | 0.91 | EGFR (0.49) | FLT1EGFRKDRMETSYK | |
| SCHEMBL6302480 | 0.91 | EGFR (0.49) | FLT1EGFRKDRMETSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964961-B2 | Thiophene derivatives useful as anticancer agents | PFIZER INC (US) | 2005-11-15 | — | — | US | claimed |
| EP-1287001-B1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1287001-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2003-03-05 | — | — | EP | claimed |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | PFIZER PRODUCTS INC. | 2002-04-11 | — | — | US | claimed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-6964961-B2 | Thiophene derivatives useful as anticancer agents | PFIZER INC (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1287001-B1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1287001-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | PFIZER PRODUCTS INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | TP53, RCC1, CCNA1 | FLT1 733/4885EGFR 532/4885ADORA2A 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.